First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges
A Rizzo, AD Ricci, G Gadaleta-Caldarola… - Expert Review of …, 2021 - Taylor & Francis
Introduction Immunotherapy has recently taken on an extremely important role in medical
oncology, as first-or later-line treatment in several tumor types, and recent years have seen …
oncology, as first-or later-line treatment in several tumor types, and recent years have seen …
VEGF signaling: Role in angiogenesis and beyond
Angiogenesis is a crucial process for tissue development, repair, and tumor survival.
Vascular endothelial growth factor (VEGF) is a key driver secreted by cancer cells …
Vascular endothelial growth factor (VEGF) is a key driver secreted by cancer cells …
Modified benzoxazole-based VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, and anti-proliferative evaluation
This work is one of our efforts to discover potent anticancer agents. We modified the most
promising derivative of our previous work concerned with the development of VEGFR-2 …
promising derivative of our previous work concerned with the development of VEGFR-2 …
[HTML][HTML] Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma
Hepatocellular carcinoma (HCC) accounts for the majority of primary liver cancers. To date,
most patients with HCC are diagnosed at an advanced tumor stage, excluding them from …
most patients with HCC are diagnosed at an advanced tumor stage, excluding them from …
Adjuvant therapy options in renal cell carcinoma—targeting the metastatic cascade
Localized renal cell carcinoma (RCC) is primarily managed with nephrectomy, which is
performed with curative intent. However, disease recurs in~ 20% of patients. Treatment with …
performed with curative intent. However, disease recurs in~ 20% of patients. Treatment with …
Targeting hypoxia-inducible factor pathways in sporadic and Von Hippel-Lindau syndrome-related kidney cancers
Hereditary and sporadic renal cell carcinomas (RCCs) are often associated with Von Hippel-
Lindau (VHL)-gene inactivation. Patients with VHL disease have an increased risk of RCC …
Lindau (VHL)-gene inactivation. Patients with VHL disease have an increased risk of RCC …
[HTML][HTML] Lenvatinib promotes antitumor immunity by enhancing the tumor infiltration and activation of NK cells
Q Zhang, H Liu, H Wang, M Lu, Y Miao… - American journal of …, 2019 - ncbi.nlm.nih.gov
Based on previous reports, the efficacy of lenvatinib against cancer is mainly attributed to its
antiangiogenic activity and its ability to suppress tumor proliferation, which are mediated by …
antiangiogenic activity and its ability to suppress tumor proliferation, which are mediated by …
New thiazolidine-2, 4-diones as potential anticancer agents and apoptotic inducers targeting VEGFR-2 kinase: Design, synthesis, in silico and in vitro studies
Background VEGFR-2 has emerged as a prominent positive regulator of cancer
progression. Aim Discovery of new anticancer agents and apoptotic inducers targeting …
progression. Aim Discovery of new anticancer agents and apoptotic inducers targeting …
[HTML][HTML] Lenvatinib enhances T cell immunity and the efficacy of adoptive chimeric antigen receptor-modified T cells by decreasing myeloid-derived suppressor cells in …
M Lu, X Zhang, X Gao, S Sun, X Wei, X Hu… - Pharmacological …, 2021 - Elsevier
Background Lenvatinib, a tyrosine kinase inhibitor, has been approved for the treatment of
several cancers. However, its regulatory activity and related mechanisms on T cell …
several cancers. However, its regulatory activity and related mechanisms on T cell …
New [1,2,4]triazolo[4,3‐c]quinazoline derivatives as vascular endothelial growth factor receptor‐2 inhibitors and apoptosis inducers: Design, synthesis, docking, and …
In continuation of our previous efforts in the field of design and synthesis of vascular
endothelial growth factor receptor (VEGFR)‐2 inhibitors, a new series of [1, 2, 4] triazolo [4, 3 …
endothelial growth factor receptor (VEGFR)‐2 inhibitors, a new series of [1, 2, 4] triazolo [4, 3 …